Close Menu

NEW YORK ─ Eysins, Switzerland-based Quotient said on Monday that it has inked a binding letter of intent with Raritan, New Jersey-based Ortho Clinical Diagnostics to terminate a former distribution agreement and related contracts and resolve all of their disputes over the former agreement.

The firms ended pending arbitration and inked a new distributor agreement focused on patient transfusion diagnostics, Quotient said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.